CS-5d Bcr-Abl and Btk small molecule kinase inhibitors

This compound inhibits in nanomolar scale for Bcr-Abl (40 nM) and sub-micromolar scale for Btk kinases (0,58 M), both are related to the genesis and progression of myeloid and lymphoid leukaemia, respectively

Contributors

Inventor	Institute
Cristian Salas	Pontificia Universidad Catolica de Chile

Cat. #:	160517
Tool sub type:	Inhibitor
Research Fields:	Cancer
Purpose:	Inhibitor

Product description:	This compound inhibits in nanomolar scale for Bcr-Abl (40 nM) and sub-micromolar scale for Btk kinases (0,58 <U+00B5>M), both are related to the genesis and progression of myeloid and lymphoid leukaemia, respectively
Molecular weight:	490.5509

Primary target:	Bcr-Abl and Btk kinases

Storage conditions:	Away from UV light
Shipping conditions:	Dry Ice
Solubility:	DMSO

References:	Bertrand et al. 2020. Bioorg Chem. 94:103361. PMID: 31699386.

Unfortunately this tool is not available through our online checkout process. Please contact our team directly to obtain further information on accessing this tool.

Enquire about this Tool

If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.

Request a license

Get technical support

New to CancerTools?

We are a trusted, non-profit platform for cancer research products, part of Cancer Research UK – by sourcing your cancer research tools from us you help fund future cancer research.

Find out more

Related Tools for Small molecules

Cat. #

Tool Name

151711

MGMT inhibitor Lomeguatrib Small Molecule (Tool Compound)

Key Info

Cat. #:	151711
Sub-type:	Inhibitor
Availability:	Please enquire for quantities and pricing
Application:	Lomeguatrib (20 mg/kg/day for 5 days) combined with Temozolomide (100 mg/kg/day for 5 days) produces a substantial tumour growth delay: median tumour quintupling time is increased by 22 days without any significant increase in toxicity, while neither of the two drugs administrated along show any antitumor activity. Lomeguatrib inactivates ATase and enhances the anti-tumour effect of Temozolomide in A375M human melanoma xenografts model. Lomeguatrib, at a single dose of 20 mg/kg i.p., produces…

View Tool

151839

Antitumoral Phortress Small Molecule (Tool Compound)

Key Info

Cat. #:	151839
Sub-type:	Antitumoral
Availability:	Please enquire for quantities and pricing
Application:	Active against breast, ovarian and renal carcinomas. Taken up into sensitive cells followed by aryl hydrocarbon receptor binding and translocation into the nucleus. Requires metabolic activation by cytochrome P450 to generate cytotoxic species. Induces expression of CYP1A1 and generates adducts in the DNA of sensitive MCF7 and IGROV-1 cells.

View Tool

152709

Dual DNA-PK/PI3K inhibitor KU-0060648 Small Molecule (Tool Compound)

Key Info

Cat. #:	152709
Sub-type:	Inhibitor
Availability:	Please enquire for quantities and pricing
Application:	KU-0060648 enhances the anti-tumour activity of etoposide in both MCF7 and SW620 xenograft models, and has single-agent activity in the MCF7 xenograft model. KU-0060648 exhibits differential effects on growth inhibition, but is not profoundly cytotoxic in a panel of human cancer cell lines. It inhibits DNA-PK and PI-3K with greater potency in MCF7 than SW620 cell using cell-based assays. Five-day exposure to 1 mM KU-0060648 inhibits cell proliferation by more than 95% in MCF7 cells but only b…

View Tool

153255

Autotaxin Inhibitor (CRT0273750) Small Molecule (Collaborative Toolkit)

Key Info

Cat. #:	153255
Availability:	3-4 weeks

View Tool

153334

HDAC3:SMRT Fluorescent Probe 2-FAM-InsP5 Small Molecule (Tool Compound)

Key Info

Cat. #:	153334
Sub-type:	Fluorescent Probe
Availability:	Please enquire for quantities and pricing
Application:	2-FAM-InsP5 [2-FAM-Ins(1,3,4,5,6)P5] is a fluorescent derivative of Ins(1,3,4,5,6)P5. 2-FAM-InsP5 activates the HDAC3:SMRT complex in a similar manner to the natural ligand, Ins(1,4,5,6)P4. The binding constant (Kd) for binding of 2-FAM-InsP5 to HDAC3:SMRT measured by a direct binding assay, 0.3 Âą 0.01 ÎźM, was approximately 10-fold lower than the Kdapp for activation of the catalytic activity of HDAC3:SMRT by Ins(…

View Tool

By Category

By Cancer Type

More

CS-5d Bcr-Abl and Btk small molecule kinase inhibitors

Contributors

Related Tools for Small molecules

Tool enquiry